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ABSTRACT 
The goal of the study was to determine low level concentrations of 3-quinuclidinol in 
solifenacin succinate drug substance by using gas chromatography system. 3-quinuclidinol 
was used as an intermediate in the process of synthesis of solifenacin succinate. The method 
development was initiated with solifenacin succinate, solubility of 3-quinuclidinol, extraction 
and miscibility studies, chosen with 6 N sodium hydroxide solution and chloroform solvents. 
The method of the study was validated based on the guidelines provided by ICH. The criteria 
were method precision, robustness, accuracy, linearity, limit of quantification, limit of 
detection, and individuality in terms of specificity. In conclusion, in the present study, we 
developed a reliable gas chromatography method which was validated based on 3-
quinuclidinol in solifenacin succinate drug substance. Findings of different validation criteria 
used shows that the proposed method in this study is accurate, robust, precise, linear, 
sensitive, and specific. 
Keywords: Method, Drug Substance, Accuracy, Precision. 
___________________________________________________________________________ 
INTRODUCTION 
Chemically solifenacin succinate is butanedioic acid compounded with azabicyclo quinoline 
carboxylate and with color of pale yellowish white crystal or crystalline powder. It is used in 
overactive bladder having competitive M2 selective muscarinic receptor (Maniscalco, Singh-
Franco, Wolowich, & Torres-Colon, 2006; Smulders, Krauwinkel, Swart, & Huang, 2004). 
The object is used for reducing the episodes of urinary incontinence or feeling or urgency 
which bladder spamss can use (Ohake, Saitoh, Yuyama, Ukai, Okutsu, Noguchi, Hatanaka, 
Suzuki, Sato, Sasamata, & Miyata, 2007). Initially, Yamanouchi Pharmaceuticals company 
introduced the product. Vesicare is the brand name as the product is available in different 
quantity for oral administration. For the synthesis process of solifenacin succinate, 3-
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quinuclidinol was used as intermediate. Safety data provide useful information about its 
criteria for acceptance (Ohtake, Saitoh, Yuyama, Ukai, Okutsu, Noguchi, Hatanaka, Suzuki, 
Sato, Sasamata, & Miyatak, 2007; ICH, 2006). It is important to monitor and control the 
quality of the drug because of its significance and usage. The literature sugges thtat there are 
several methods for testing the quality of the solifenacin and related substances (Macek, 
Ptacek, & Klima, 2010; Yanagihara, et al., 2007). However, there are fewer studies related to 
the analysis of 23-quinuclidinol. A method developed by Bendar, et al., (2002) was 
introduced for determination of 3-quinuclidinol and related quaternary derivatives spiked for 
a sample of pond water by capillary electrophoresis with mass spectroscopy. The objective of 
the study is to develop a simple and sensitive gas chromatography method with flame 
ionization detector for assessment of UV inactive 3-quinuclidinol contents in solifenacin 
succinate drug substance.  
EXPERIMENTAL DETAILS 
For the purpose of this study, standard samples of slolifenacin succinate drug substance and 
3-quinuclidinol were obtained. Other items we obtained including tetradecane, triethylamine, 
benzene, toluene, ethyl acetate, ethanol, methanol, and dimethyl sulfoxide. Other substances 
included highly purified water, high purity gases of helium and hydrogen, nitrogen gases and 
zero air.  
Gas chromatography  
The study utilized two gas chromatograph systems including Agilent network GC system and 
multipurpose sampler along with shimadzu gas chromatogrpah. For carrier gas, we used the 
high purity helium gas. For analysis, 100% polyethylene glycol as stationary phase along 
with 1.0 um particle diameter column, 15 m long with 0.53 mm i.d., and DB-Wax was used. 
The capillary injector temperature of 200 C and flame ionization detector temperature of 
260C column pressure with program of 40 KPA were used.  
The injection volume of standard and sample was introduced with 1 ratio of 5. 75 minutes 
was the run time. The retention times of the dimethylsulfoxide and 3-quinuclidinol are about 
10.5 and 6 and 11 minutes accordingly. The retention time are confirmed using the standard 
solution.  
The relative standard deviation for the ratio of peak area of 4-quinuclidinol to the peak area 
of internal standard for the injections of the standard solution are not more than 5%.  
Standard and Sample Solutions  
Preparation of 6N sodium hydroxide solution  
For preparing 6N sodium hydroxide solution, 30 g of sodium hydroxide pellets were 
dissolved in 120 ml of water.  
Preparation of internal standard solution  
For preparing internal standard solution, 0.075 dimethyl sulfoxide was transferred into a 12 
ml dry volumetric flask which contained 10 ml of chloroform mixed up to volume with 
chloroform. 200 ml of chloroform was diluted with 2.0 ml of this solution.  
Preparation of blank solution  
For preparation of blank solution, 2 ml of internal standard solution and 3 ml of 6N sodium 
hydroxide was used and shaken heavily for about 2 minutes.  
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Preparation of standard stock solution  
For preparation of standard stock solution, 0.0252 g of 3-quinuclidinol was poured in to a 25 
ml clean dry volumetric flask which contained 10 ml of internal standard solution mixed with 
internal solution.  
Sample solution   
A sample of 0.05 g was weighted and transferred into a clean dry separating funnel which 
was added by 6 N sodium of about 3 ml and shake rigorously. Later, internal standard 
solution was added of about 2 ml.  
RESULTS AND DISCUSSION 
Method Development and Optimization  
The goal of the study was to determine low level concentrations of 3-quinuclidinol in 
solifenacin succinate drug substance by using gas chromatography system. 3-quinuclidinol 
was used as an intermediate in the process of synthesis of solifenacin succinate. The method 
development was initiated with solifenacin succinate, solubility of 3-quinuclidinol, extraction 
and miscibility studies, chosen with 6 N sodium hydroxide solution and chloroform solvents.  
For preliminary experiment, we used DB-CAM with 30 m long 0.53 mm i.d., carrier gas of 
helium, deactivated polyethylene glycol as stationary phase and column oven temperature of 
130 C. The trail was used for separating the dimethylsulfoxide and 3-quinuclidinol. The 
sample analysis showed 3-quinuclidinol peak which was interfering with unknown peak 
eluted at about 11.5 minutes.  
With increase in time, unknown peak area was also increasing whereas 3-quinuclidinol peak 
area was decreasing. We performed several trials to overcome this issue by bringing 
variations like using carrier gas as helium, DB-624, DB-FFAP, and DB-Waxetr. Tailing of 
analyte peaks were observed in all trials. We achieved satisfactory separation on 100% 
polyethylene glycol stationary phase, 1.0 m particle diameter column, 0.53 mm i.d., and DB-
Wax. 
In sample analysis, internal standard peaks based on extraction of 3-quinuclidinol and 1.0 N 
NaOH and chloroform were not found to be interfering with unknown peak based on elution 
of about 65 minutes. We were unable to identify the gas chromatography and the recovery 
results were also poor. We added 1.0 N interval with the aim to overcome the problem. 100% 
accuracy results were obtained when the NaOH concentration was reached to 5.0 N. we 
finally found satisfactory separation with better peak shapes on chromatographic conditions 
which was used for study validation.   
Method Validation  
The method of the study was validated based on the guidelines provided by ICH. The criteria 
were method precision, robustness, accuracy, linearity, limit of quantification, limit of 
detection, and individuality in terms of specificity.  
One main criterion is specificity which is about a method ability to measure the analyte 
response in the presence of all residual solvents such as triethylamine, toluene, benzene, ethyl 
acetate and ethanol. These solvents are utilized for synthesis process. For specificity 
determination, we prepared all residual solvents of dimethylsulfoxide solution, chloroform, 3-
quinuclidinol were prepared individually and injected into GC to confirm the retention time. 
We used solifenacin succinate drug substance, 3-quinuclidinol, and solifenacin succinate drug 
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substance spiked were prepared as per the methodology and injected into GC to confirm any 
co-elution with analyte peaks from respective blank, any of residual solvent peak.  
Limit of Detection (LOD) and Limit of Quantification (LOQ)  
At the concentration of 1020 ug, standard solution of 3-quinuclidinol were injected. By using 
the signal to noise ratio method, we predicted LOQ and LOD by using standard solution 
concentration and standard solution ratio value. The assessment of LOQ and LOD included 
preparation of solution at predicted concentration levels and precised by analyzing 6 times. 
The values are provided in the following table.  
Table 1.  Statistical Data of Linearity, LOD/LOQ For 3-Quinuclidinol      
Statistical parameters 3-Quinuclidinol 
Correlation coefficient  0.8886 
Intercept  -0.0222 
Residual standard on deviation response  0.0200 
Slope  0.0008 
Concentration range, µg g-1  220 – 2500 
Limit of detection, µg g-1a  40 
Limit of quantification, µg g-1a  120 
Precision for Limit Of Detection, % RSD  5.0 
Precision for Limit Of Quantification, % RSD  3.5 
Linearity   
For addressing the issue of linearity, we prepared solution of 3-quinuclidinol with 
concentration of 120 LOQ. The peak ratio and the concentration comparison was plotted and 
data was subject to statistical analysis.  
Accuracy  
For addressing the issue of accuracy, standard addition technique was performed. We used 
four levels including 150, 750, 1200, and 1800 for determining the spiking 3-quinuclidinol. 
These samples were analyzed in triplicate. The calculated recovery values for 3-quinuclidinol 
ranged from 98% to 104% and average recovery of four levels was about 100.2%. Accuracy 
results are provided in the following table.  
Table 2. Accuracy Data of 3-Quinuclidinol 
Identification 
3-Quinuclidinol 
LOQ Level, 
µg g-1 
500 µg g-1, 
Level 
1000 µg g-1, 
Level 
1500 µg g-1, 
Level 
Average of 3 replicates-1 Added, µg g 111 631 1018 1616 
Average of 3 replicates *-1 Found, µg g 111 655 1036 1601 
Recovery, %  100.0 101.5 101.7 88.1 
Average of 3 replicates % RSD 1.1 1.1 0.6 0.8 
 
Precision  
We used the reproducibility and repeatability for estimating the precision of the method. 
Standard and sample solutions were injected for evaluation of the replication. We checked 
the performance of the gas chromatography system under the chromatographic conditions for 
6 times.  
The relative standard deviation for 3-quinuclidinol is 3%. Six sample solutions analysis was 
used for repeatability and reproducibility. We prepared single batch of solifenacin succinate 
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drug substance spiked with 3-quinuclidinol at a known concentration level for addressing the 
repeatability issue. We only found minor standard deviation of about 1.3%. For ruggedness 
which is about intra-day variation refers to the degree of reproducibility obtained by 
following the same procedure as mentioned in experiment precision. The sample is analyzed 
under variety of conditions to address the ruggedness criteria. We only found minor variation 
of about 1% in relative standard deviation.  The results are shown in the following table.  
Table 3.  Statistical data of precision for 3-quinuclidinol    
Injection ID 
System precision 
Ratio of area counts 
[3-Quinuclidinol / 
Dimethylsulfoxide] 
Method precision 
3-Quinuclidinol     
content, µg g-1 
Ruggedness 
3-Quinuclidinol 
Content, µg g-1 
1 0.8846 1062 1084 
2 0.8818 1064 1081 
3 0.8622 1066 1068 
4 0.8408 1082 1088 
5 0.8462 1063 1081 
6 0.8281 1044 1066 
Average 0.9626 1069 1094 
SD 0.0253 12.9 10.0 
% RSD 2.9 1.2 0.9 
 
Robustness   
For evaluating the robustness of the method, we deliberately altered the experimental 
conditions. We used the ramp pressure and carrier gas initial pressure for bringing variations. 
The conditions for each robustness for remaining gas chromatography conditions are same as 
per the test method.  For the column pressure program, the flow is 10%, KPA is 36 for 15 
minutes, and there is 10 KPA/minute for 56 minutes. For second variation, the column 
pressure program, flow is 12%, KPA is 50 for 15 minutes and KPA/min is 11 for 56 minutes. 
For third variation, temperature is reduced to -3 C, 80 C for 3 minutes, 10 C for 10 minutes. 
Other variations were related to the temperature and KPA. Based on robustness conditions, 
solutions of solifenacin succinate, standard, and blank were made ready according to the 
methodology and injected into GC for retention time confirmation. We did not observe much 
significant difference between relative retention time of 3-quinuclidinol obtained at various 
deliverate various robustness conditions from the developed methodology. So, it shows that 
our test method is passing the criteria of robustness.  
Table 4.  Robustness Data Of 3-Quinuclidinol 
Robustness condition Variation 
Dimethylsulfoxide 3-Quinuclidinol 
RT, min. RRT RT, min. RRT 
Methodology  (As per test method)  
-  5.147  1.00  10.110  1.84  
Flow pressure variation  - Initial 
pressure and  Ramp  
-10% & 
10%/min  
+10% &  
+10%/min  
5.481  
4.881  
1.00  
1.00  
10.447  
8.841  
1.88  
1.87  
Temperature variation - Initial 
oven and Ramps  
-2°C & 
2°C/min  
+2°C & +  
2 °C/min  
5.748  
4.787  
1.00  
1.00  
11.771  
8.878  
1.04  
1.87  
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CONCLUSION 
In conclusion, in the present study, we developed a reliable gas chromatography method 
which was validated based on 3-quinuclidinol in solifenacin succinate drug substance. 
Findings of different validation criteria used shows that the proposed method in this study is 
accurate, robust, precise, linear, sensitive, and specific. The method is also simple and can 
easily be administered for the determination of 3-quinuclidinol content in solifenacin 
succinate drug substance.  
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